Deal Health

Deal health is an assessment of how likely an open deal is to close successfully, based on signals about its momentum, engagement, and risk, rather than just the rep's gut feeling. It is a read on whether a deal is genuinely progressing or quietly stalling, often surfaced as a score or status in modern sales tools.

Reps are notoriously optimistic about their deals, and a pipeline full of "looking good" deals that never close is a common, costly problem. Deal health brings evidence to that judgment, using observable signals to flag which deals are truly healthy and which are at risk, before the close date arrives.

What deal health is

Deal health evaluates an individual opportunity against indicators that correlate with closing: is the buyer engaged, are multiple stakeholders involved, are next steps defined and on schedule, has the deal stalled between stages? Combined, these give a picture of the deal's true state, often expressed as a health score (green/yellow/red or a number). The point is to replace optimism and recency bias with a signal-based read on each deal's real odds.

Signals of deal health

How deal health is assessed

Deal health is increasingly scored automatically by analyzing activity and engagement data, rather than relying on the rep's say-so.

Modern revenue intelligence tools assess deal health by reading captured signals, email and meeting engagement, stakeholder involvement, stage progression, time since last activity, and flagging deals that look at risk. This turns deal health from a subjective opinion into a data-driven signal that managers and reps can act on, and it feeds directly into deal management and forecasting.

Why deal health matters

• Early risk detection. It flags stalling deals while there is still time to act, not after they are lost.
• Better forecasting. Health-scored deals make the forecast more honest than rep optimism alone.
• Focus. It shows which deals need attention and which are genuinely on track.
• Coaching. Health signals reveal where a rep needs help advancing a deal.

Deal health and forecasting

Deal health is a direct antidote to the optimism that corrupts forecasts. A deal a rep calls "90% likely" but that has gone quiet, lost its champion, and has no next step is, by its signals, at risk, and deal health surfaces that gap. Used in forecasting, it grounds the pipeline view in evidence rather than hope, complementing weighted pipeline and improving forecast accuracy. The aim is a pipeline whose stated health matches its real odds.

Common deal health mistakes

• Relying on rep optimism. Gut-feel health assessments are biased; signals are more honest.
• Ignoring quiet deals. A deal that has gone silent is at risk even if its stage looks advanced.
• Score without action. Flagging an at-risk deal but not intervening wastes the signal.
• Single-signal reliance. One indicator (e.g. stage) is not deal health; it is the combination that matters.

Deal health replaces optimism with evidence, reading the signals that reveal whether an open deal is truly progressing or quietly dying. Scored from real activity and acted on early, it catches at-risk deals in time, sharpens the forecast, and focuses attention on the deals that need it, before the close date delivers the bad news.